NMN/NR (Nicotinamide Mononucleotide/Riboside) Pediatric Dosing (Under 12): What Clinicians and Parents Need to Know

Why There Is No Established Pediatric Dose for NMN or NR

The short answer is that no one has run the trials. Every human pharmacokinetic and efficacy study of NMN or NR has enrolled adults, most of them over 40, and none has included participants under 18. Without age-stratified pharmacokinetic data, weight-based dosing for a 6-year-old or a 10-year-old is not a calculation anyone can perform responsibly.

The FDA's pediatric drug development framework, described in the Pediatric Research Equity Act (PREA) and the Best Pharmaceuticals for Children Act (BPCA), requires that sponsors collect pediatric safety and dosing data when a new drug or biologic is studied in adults [1]. NMN and NR are not currently approved drugs, but the FDA's November 2022 determination that NMN is excluded from the dietary supplement definition because it was first studied as an investigational new drug means NMN now sits in a regulatory gray zone where neither supplement nor drug rules cleanly apply [2].

The Regulatory Status Problem

The FDA's position, published in a November 2022 response letter to an agency notification, concluded that NMN does not meet the statutory definition of a dietary supplement under 21 U.S.C. § 321(ff)(3)(B)(ii) [2]. That conclusion removes the legal pathway by which a manufacturer could sell NMN as a supplement, including selling it to parents for use in children.

NR occupies a different position. The FDA has accepted several GRAS (Generally Recognized as Safe) notifications for NR in adult food and supplement contexts, but those notifications did not include pediatric sub-populations [3]. GRAS status in adults does not automatically extend safety coverage to children under 12, whose renal clearance rates, hepatic enzyme maturation, and NAD+ metabolic flux differ meaningfully from adult values.

What the Adult Pharmacokinetic Data Actually Shows

In the most rigorous NMN pharmacokinetic study published to date, Irie et al. (2020) administered single oral doses of 100 mg, 250 mg, and 500 mg NMN to 10 healthy Japanese men and measured plasma NMN, NAD+, and downstream metabolite concentrations over 5 hours [4]. Blood NAD+ in whole blood rose significantly at the 500 mg dose (P<0.05 vs. Baseline), with peak nicotinamide levels appearing at approximately 2 to 3 hours post-dose. No serious adverse events occurred.

The study tells us something about adult male absorption kinetics. It tells us nothing about how an 8-year-old's gut, liver, and red blood cells handle the same compound. Children's renal tubular secretion matures gradually through age 12, and hepatic CYP enzyme expression patterns differ from adult patterns through at least mid-adolescence [5]. Extrapolating adult pharmacokinetic data to children using simple body-weight scaling is considered unreliable by the FDA's own pediatric pharmacology guidance [1].

What the Best Available Adult Evidence Actually Shows

Understanding the adult evidence base is necessary before explaining its limits for pediatric use. The two most-cited human RCTs are Yoshino et al. (2021) and Irie et al. (2020).

Yoshino et al. (Science, 2021)

Yoshino and colleagues enrolled 25 postmenopausal women with prediabetes or obesity in a 10-week, double-blind, placebo-controlled crossover trial [6]. Participants received 250 mg oral NMN daily. Skeletal muscle NAD+ metabolome increased significantly, and insulin-stimulated glucose disposal improved (as measured by hyperinsulinemic-euglycemic clamp), but body weight and plasma lipids did not change significantly.

The trial population was postmenopausal women aged 55 to 75. The physiology of a prepubescent child differs from this population on nearly every relevant axis: hormonal milieu, metabolic rate, body composition, and NAD+ biosynthetic enzyme expression. The trial's findings should not be extrapolated to children under 12 [6].

Irie et al. (2020) Safety Data

The Irie et al. (2020) study additionally confirmed that NMN at doses up to 500 mg in a single administration produced no clinically significant changes in heart rate, blood pressure, oxygen saturation, or standard chemistry panels in adult men [4]. A 12-week safety extension by the same group (Kawamura et al., not yet peer-reviewed as of this writing) reported no serious adverse events at 1,200 mg/day in adults.

Again, none of this data was gathered in children. The absence of harm in adults does not constitute a safety assurance for a 25 kg child.

NR Adult Trials

For NR, a randomized crossover pharmacokinetic trial by Trammell et al. (Cell Metabolism, 2016) enrolled 12 healthy adults and showed that a single 1,000 mg dose of NR raised whole-blood NAD+ by as much as 2.7-fold over baseline within 8 hours [7]. A later 6-week parallel-group trial by Dollerup et al. (American Journal of Clinical Nutrition, 2018) assigned 40 overweight men to 2,000 mg NR daily or placebo and found no significant metabolic benefit at that dose [8].

Neither trial enrolled anyone under 18. The Dollerup negative result at 2,000 mg/day underscores that even in adults, the dose-response relationship for NR remains incompletely characterized.

NAD+ Biology in the Developing Child

Children are not simply small adults for NAD+ metabolism. Three considerations matter most.

Baseline NAD+ Levels Are Already High in Youth

Circulating NAD+ concentrations in whole blood decline with age. Studies measuring NAD+ in human peripheral blood mononuclear cells and whole blood consistently show that younger individuals have higher baseline NAD+ than older adults [9]. The rationale most frequently cited for NMN or NR supplementation in adults is to restore declining NAD+ toward youthful levels. In children under 12, NAD+ levels are not declining. Supplementing a child whose NAD+ is already at or near its biological ceiling provides no established benefit and introduces unknown risk.

The Salvage Pathway Is Different in Growing Tissue

Rapidly dividing cells in a growing child rely heavily on the NAD+ salvage pathway enzyme NAMPT (nicotinamide phosphoribosyltransferase) to recycle nicotinamide into NAD+ [10]. Exogenous NMN bypasses part of this pathway by entering cells via specific transporters and converting directly to NAD+. Whether flooding this pathway in growing tissue alters cell-cycle regulation, differentiation signaling, or sirtuin-dependent epigenetic programming is entirely unknown.

PARP Activation and DNA Repair

NAD+ is a substrate for PARP (poly-ADP-ribose polymerase) enzymes that repair DNA strand breaks. In tissues undergoing rapid growth and replication, PARP activity is already elevated. Excess NAD+ availability could theoretically alter PARP-mediated signaling in ways that have not been studied in pediatric tissue [10].

FDA Regulatory Framework and What It Means for Prescribers

The FDA's exclusion of NMN from the dietary supplement definition is the most consequential regulatory event in this space [2]. It means:

1. A licensed clinician who recommends NMN to a patient is recommending a compound that the FDA has determined cannot legally be sold as a supplement.
2. Compound pharmacies cannot legally compound NMN for pediatric patients under the current regulatory reading.
3. Manufacturers selling NMN in the United States are doing so in violation of the FD&C Act, per FDA's own letter.

The FDA's guidance on pediatric drug studies, published under 21 CFR Part 50 Subpart D, requires special protections for children in clinical investigations and mandates that the anticipated benefit justify any risk [1]. Because NMN has no proven benefit in any population and no pediatric safety data, no IRB should approve a pediatric dosing trial without substantial preclinical justification. None exists publicly as of mid-2025.

What Clinicians Should Document

Any clinician who fields a parent's question about NMN or NR for a child under 12 should document in the chart:

• That no validated pediatric dose exists.
• That the FDA has excluded NMN from supplement status.
• That the clinician recommended against use outside a clinical trial.
• That the family was counseled on the established, well-characterized NAD+ precursor options (see next section).

Established NAD+ Precursors With Pediatric Dosing Data

If a clinician has a clinical reason to support NAD+ metabolism in a child, niacin (nicotinic acid) and nicotinamide have well-established pediatric reference ranges published by the National Academies of Sciences, Engineering, and Medicine (NASEM) Dietary Reference Intakes [11].

Dietary Reference Intakes for Niacin in Children

The NASEM DRI for niacin (expressed as niacin equivalents, NE) in children is as follows [11]:

| Age Group | Adequate Intake / RDA (mg NE/day) | Tolerable Upper Intake Level (mg/day) | |---|---|---| | 1 to 3 years | 6 mg NE/day (RDA) | 10 mg/day | | 4 to 8 years | 8 mg NE/day (RDA) | 15 mg/day | | 9 to 13 years | 12 mg NE/day (RDA) | 20 mg/day |

These values apply to nicotinic acid and nicotinamide forms. NMN and NR are metabolized to nicotinamide as a downstream product in humans, but the pharmacokinetic profile is different enough that DRI values for niacin cannot be used to extrapolate a safe NMN or NR dose in children [12].

Why Niacin and Nicotinamide Are Not the Same as NMN

Niacin enters NAD+ biosynthesis via the Preiss-Handler pathway, while NMN enters via the NMN-specific transporter Slc12a8 or is dephosphorylated to NR before cell entry. The metabolic intermediates differ, the tissue distribution may differ, and the degree of NAD+ augmentation in specific compartments differs [12]. A child meeting the niacin DRI is not receiving the equivalent of an adult NMN dose, nor vice versa.

Clinical Scenarios Where Parents Ask About NMN or NR for Children

Mitochondrial Disease

Parents of children with mitochondrial disorders sometimes ask about NAD+ precursors based on case reports and small adult series. For these patients, the standard of care involves referral to a metabolic geneticist. Riboflavin, CoQ10, and specific B-vitamin supplementation have more pediatric evidence than NMN or NR [13]. No randomized trial of NMN or NR in pediatric mitochondrial disease has been published.

Autism Spectrum Disorder

A small number of online communities have circulated the idea that NAD+ supplementation may benefit children with ASD. No clinical evidence supports this claim. The only registered trial examining NAD+ precursors in ASD-related outcomes as of mid-2025 is an adult pilot study (ClinicalTrials.gov NCT05648877), and its results are not yet published.

"Anti-aging" or Longevity Use in Healthy Children

The rationale for NMN or NR supplementation in adults is to compensate for age-related NAD+ decline. Children under 12 do not experience this decline. There is no scientific rationale for longevity supplementation in this age group, and the term "anti-aging" has no clinical meaning in pediatric practice.

Monitoring Framework If a Child Has Already Been Exposed

Some families arrive at a clinical appointment after a child has already received NMN or NR, often purchased online. The following monitoring approach is reasonable, though not evidence-based in this specific context:

Immediate Assessment

• Obtain a full medication and supplement history including dose, frequency, and duration.
• Check a basic metabolic panel, complete blood count, and liver function tests, since NMN is cleared partly by hepatic and renal pathways [4].
• Ask about any symptoms: flushing (more typical of nicotinic acid), nausea, rash, or GI distress.

Short-Term Follow-Up

• If labs are normal and the child is asymptomatic, discontinue the supplement and repeat labs in 4 to 6 weeks.
• Report adverse events to the FDA MedWatch system (FDA.gov/safety/medwatch) regardless of whether a causal link is established [2].
• Document thoroughly. The pediatric adverse event reporting database for supplements is thin, and every report contributes to the evidence base.

What to Tell Parents: Plain-Language Talking Points

Parents asking about NMN or NR for a child under 12 usually arrive with good intentions and information from wellness influencers or longevity podcasts. A direct, non-dismissive clinical conversation covers four points:

First, the child's NAD+ levels are already high. The supplement addresses a problem the child does not have.

Second, no dose has ever been tested in children under 12. The adult doses in published trials (250 mg to 2,000 mg/day) were not weight-adjusted and were not studied in developing bodies.

Third, the FDA has specifically flagged NMN as a compound that cannot legally be sold as a dietary supplement in the United States. The product a parent purchased online may be operating outside federal law.

Fourth, if there is an underlying health concern driving the question, that concern deserves direct evaluation. A child's fatigue, metabolic irregularity, or developmental difference warrants a workup, not a supplement.